|Videos|April 22, 2021
Impact of Initial Therapy on Front Line Maintenance Treatment Choice in Advanced Ovarian Cancer
Author(s)Rebecca Previs, MD
An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.
Advertisement
Advertisement
Related to this article
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5